Goldman Sachs, AbbVie And A Major Chipmaker: CNBC's 'Final Trades'
Portfolio Pulse from Avi Kapoor
On CNBC's 'Halftime Report Final Trades,' analysts recommended Taiwan Semiconductor Manufacturing (TSM), AbbVie (ABBV), and Goldman Sachs (GS). TSM is expected to announce a second Japanese plant, which could boost its stock. AbbVie, with an upgraded rating from William Blair and upcoming earnings release, is also favored. Goldman Sachs is seeking new talent to grow its asset and wealth management divisions, which recently saw a 23% revenue surge. All three companies experienced slight stock price movements on Monday.
January 30, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie received an analyst upgrade and is expected to release its Q4 earnings, which could influence its stock price.
The upgrade by William Blair and the upcoming earnings report, with expected strong EPS and sales, could lead to increased investor confidence and a potential rise in ABBV's stock price.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 80
POSITIVE IMPACT
Goldman Sachs is expanding its asset and wealth management teams after a 23% revenue increase in these divisions, which may positively impact its stock.
The strategic hiring initiative and recent earnings boost from its asset and wealth management divisions could lead to positive market perception and a short-term uptick in GS's stock price.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
TSM is expected to announce a new Japanese plant, which could positively impact its stock as it reinforces its manufacturing capabilities.
The anticipation of a new plant announcement in Japan could lead to positive investor sentiment, potentially driving TSM's stock price up in the short term.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80